A comparative cross-sectional study of Chinese and American lung caner drug trial in 2019
- VernacularTitle:2019 中美肺癌药物临床试验横断面比较研究
- Author:
WANG Shuhang
1
;
FANG Yuan
1
;
HUANG Huiyao
1
;
WU Dawei
1
;
YU Yue
1
;
LI Ning
1
Author Information
1. National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P.R.China
- Publication Type:Journal Article
- Keywords:
Lung cancer;
clinical studies;
China versus the United States;
primary tested drug ratio;
target abundance
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2020;27(03):327-331
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the current status of clinical studies regarding lung cancer between China and the United States in 2019, and to indicate the weakness, trend and future development direction of clinical studies drug treatment in China. Methods The data of lung cancer clinical studies from January 1st to November 30th, 2019 in China and the United States were retrieved and analyzed through Informa pharmaprojects database. Results The United States was superior on the number of projects (128 vs. 156) and research institutions (743 vs. 2 250). Compared with the United State, there were more phase Ⅲ confirmatory researches (19.5% vs. 10.3%), bioequivalent drug researches (3.1% vs. 0%), and researches initiated by academic institutions (39.8% vs. 28.1%) in China. The United States exhibited advantages in phaseⅠ andⅠ/Ⅱstudies (25.8% vs. 60.3%), immunodrugs (49.2% vs. 60.3%), primary tested drug ratio (61.7% vs. 93.6%), targets abundance (32.9% vs. 69.6%), and chimeric antigen receptor-T (CAR-T, 0.7% vs. 7.1%). Conclusion Compared with the United States, China should pay more attention to innovative drug investigations in early phase of clinical studies, especially novel immune agents, vaccines, and CAR-T.
